Literature DB >> 10074516

Molecular evidence for heterogeneity of the multiple-drug-resistant Mycobacterium tuberculosis population in Scotland (1990 to 1997).

Z Fang1, C Doig, A Rayner, D T Kenna, B Watt, K J Forbes.   

Abstract

Multiple-drug-resistant Mycobacterium tuberculosis (MDR-MTB) has been well studied in hospitals or health care institutions and in human immunodeficiency virus-infected populations. However, the characteristics of MDR-MTB in the community have not been well investigated. An understanding of its prevalence and circulation within the community will help to estimate the problem and optimize the strategies for control and prevention of its development and transmission. In this study, MDR-MTB isolates from Scotland collected between 1990 and 1997 were characterized, along with non-drug-resistant isolates. The results showed that they were genetically diverse, suggesting they were unrelated to each other and had probably evolved independently. Several new alleles of rpoB, katG, and ahpC were identified: rpoB codon 525 (ACC-->AAC; Thr525Asn); katG codon 128 (CGG-->CAG; Arg128Gln) and codon 291 (GCT-->CCT; Ala291Pro); and the ahpC synonymous substitution at codon 6 (ATT-->ATC). One of the MDR-MTB isolates from an Asian patient had an IS6110 restriction fragment length polymorphism pattern very similar to that of the MDR-MTB W strain and had the same drug resistance-related alleles but did not have any epidemiological connection with the W strains. Additionally, a cluster of M. tuberculosis isolates was identified in our collection of 715 clinical isolates; the isolates in this cluster had genetic backgrounds very similar to those of the W strains, one of which had already developed multiple drug resistances. The diverse population of MDR-MTB in Scotland, along with a low incidence of drug-resistant M. tuberculosis, has implications for the control of the organism and prevention of its spread.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074516      PMCID: PMC88639     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement.

Authors:  K Weyer; H H Kleeberg
Journal:  Tuber Lung Dis       Date:  1992-04

2.  Usefulness of Mycobacterium tuberculosis genomic mutations in the genes katG and inhA for the prediction of isoniazid resistance.

Authors:  P Dobner; S Rüsch-Gerdes; G Bretzel; K Feldmann; M Rifai; T Löscher; H Rinder
Journal:  Int J Tuberc Lung Dis       Date:  1997-08       Impact factor: 2.373

3.  A general method applicable to the search for similarities in the amino acid sequence of two proteins.

Authors:  S B Needleman; C D Wunsch
Journal:  J Mol Biol       Date:  1970-03       Impact factor: 5.469

4.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

5.  IS6110 fingerprinting of drug-resistant Mycobacterium tuberculosis strains isolated in Germany during 1995.

Authors:  S Niemann; S Rüsch-Gerdes; E Richter
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

6.  Nationwide survey of drug-resistant tuberculosis in the United States.

Authors:  A B Bloch; G M Cauthen; I M Onorato; K G Dansbury; G D Kelly; C R Driver; D E Snider
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

7.  Determination of in vitro susceptibility of mycobacteria to ansamycin.

Authors:  L B Heifets; M D Iseman
Journal:  Am Rev Respir Dis       Date:  1985-09

8.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

Authors:  A Banerjee; E Dubnau; A Quemard; V Balasubramanian; K S Um; T Wilson; D Collins; G de Lisle; W R Jacobs
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

9.  Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients.

Authors:  C Beck-Sagué; S W Dooley; M D Hutton; J Otten; A Breeden; J T Crawford; A E Pitchenik; C Woodley; G Cauthen; W R Jarvis
Journal:  JAMA       Date:  1992-09-09       Impact factor: 56.272

10.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

View more
  12 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001.

Authors:  Igor Mokrousov; Olga Narvskaya; Tatiana Otten; Elena Limeschenko; Lidia Steklova; Boris Vyshnevskiy
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis.

Authors:  Márcia Susana N Silva; Simone G Senna; Marta O Ribeiro; Andréia R M Valim; Maria Alice Telles; Afrânio Kritski; Glenn P Morlock; Robert C Cooksey; Arnaldo Zaha; Maria Lucia R Rossetti
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

4.  Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil.

Authors:  Rosilene Fressatti Cardoso; Robert C Cooksey; Glenn P Morlock; Patricia Barco; Leticia Cecon; Francisco Forestiero; Clarice Q F Leite; Daisy N Sato; Maria de Lourdes Shikama; Elsa M Mamizuka; Rosario D C Hirata; Mario H Hirata
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Structural and functional divergence of MutS2 from bacterial MutS1 and eukaryotic MSH4-MSH5 homologs.

Authors:  Josephine Kang; Shuyan Huang; Martin J Blaser
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

6.  Antibiotic resistance and single-nucleotide polymorphism cluster grouping type in a multinational sample of resistant Mycobacterium tuberculosis isolates.

Authors:  M Brimacombe; M Hazbon; A S Motiwala; D Alland
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

7.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

8.  Use of DNA extracts from Ziehl-Neelsen-stained slides for molecular detection of rifampin resistance and spoligotyping of Mycobacterium tuberculosis.

Authors:  A G M Van Der Zanden; E M Te Koppele-Vije; N Vijaya Bhanu; D Van Soolingen; L M Schouls
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

9.  Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis.

Authors:  Hiroki Ando; Yuji Kondo; Toshinori Suetake; Emiko Toyota; Seiya Kato; Toru Mori; Teruo Kirikae
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

10.  Extensive transmission of isoniazid resistant M. tuberculosis and its association with increased multidrug-resistant TB in two rural counties of eastern China: a molecular epidemiological study.

Authors:  Yi Hu; Sven Hoffner; Weili Jiang; Weibing Wang; Biao Xu
Journal:  BMC Infect Dis       Date:  2010-02-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.